Purpose: The impact of EGFR tyrosine kinase inhibitors (TKI) on the tumor immune
microenvironment (TME) in non–small cell lung cancer (NSCLC) is unclear. Experimental …

Background The efficacy of programmed death-1 blockade in epidermal growth factor
receptor gene (EGFR) mutation-positive non-small-cell lung cancer (NSCLC) patients with …

Lung cancer is a leading cause of cancer-related deaths worldwide. About 10–30% of
patients with non-small cell lung cancer (NSCLC) harbor mutations of the EGFR gene. The …

Patients with EGFR mutations showed unfavorable response to programmed cell death-1
(PD-1) blockade immunotherapy in non-small cell lung cancer (NSCLC). Yet the underlying …

Introduction Epidermal growth factor receptor (EGFR) mutation status was reported to be
associated with programmed death-ligand 1 (PD-L1) expression. However, the molecular …

Objectives The efficacy of immunotherapy in epidermal growth factor receptor (EGFR)-
activating non-small cell lung cancer (NSCLC) is limited. However, a series of patients with …

Background Insertions in exon 20 (Ex20ins) of epidermal growth factor receptor (EGFR) and
human epidermal growth factor receptor 2 (HER2) are relatively insensitive to first‐and …

Lung cancer is the leading cause of cancer-related deaths worldwide. Immune checkpoint
inhibitors, including monoclonal antibodies against programmed death-1 (PD-1) and …

Immune checkpoint inhibitors targeting the programmed cell death receptor/ligand 1 (PD‐
1/PD‐L1) pathway have profoundly improved the clinical management of non‐small‐cell …

Methods One-hundred and seventy patients with advanced NSCLC were explored. Paraffin-
embedded tumour sections were stained with PD-L1 antibody. EGFR mutation was …